Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome

Clinical Infectious Diseases

Volumn 37, Issue SUPPL. 2, 2003, Pages

  Grunfeld, Carl ^a,b   Tien, Phyllis ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LOW DENSITY LIPOPROTEIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LIPOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARM; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FACE; GENETIC DISORDER; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE FUNCTION TEST; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEG; LIPID METABOLISM; LIPOATROPHY; METABOLIC DISORDER; METABOLIC SYNDROME X; METABOLITE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ADIPOSE TISSUE; GLUCOSE BLOOD LEVEL; HIV ASSOCIATED LIPODYSTROPHY; METABOLISM;

ADIPOSE TISSUE; ANTI-HIV AGENTS; BLOOD GLUCOSE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN; LIPOPROTEINS; METABOLIC DISEASES; METABOLIC SYNDROME X;

EID: 0042262057     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375886     Document Type: Review

References (61)

1. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-505.
2. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998; 351:867-70.
3. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27:68-72.
4. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-5.
5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
6. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999; 21:107-13.
7. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13:465-71.
8. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997; 350:1596.
9. Stricker RB, Goldberg B. Fat accumulation and HIV-1 protease inhibitors. Lancet 1998; 352:1392.
10. Striker R, Conlin D, Marx M, Wiviott L. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis 1998; 27:218-20.
11. Engelson ES, Kotler DP, Tan Y, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999; 69:1162-9.
12. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12:F37-9.
13. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13:735-7.
14. Saint-Marc T, Touraine JL. "Buffalo hump" in HIV-1 infection. Lancet 1998; 352:319-20.
15. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
16. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:228-37.
17. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-67.
18. Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25:937-8.
19. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Body shape changes in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:307-8.
20. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997; 350:713-4.
21. Walli R, Goebel FD, Demant T. Impaired glucose tolerance and protease inhibitors. Ann Intern Med 1998; 129:837-8.
22. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-70.
23. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
24. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998; 12:1393-4.
25. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27:77-81.
26. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-5.
27. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999; 84:1925-31.
28. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999; 21:209-16.
29. Dever LL, Oruwari PA, Figueroa WE, O'Donovan CA, Eng RH. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother 2000; 34:580-4.
30. Dube MP, Edmondson-Melancon H, Qian D, Aqeel R, Johnson D, Buchanan TA. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 2001; 27:130-4.
31. Dube MP. Lipodystrophy and insulin resistance in patients with HIV. J Acquir Immune Defic Syndr 2001; 27:506-7.
32. Bonnet F, Saves M, Droz C, et al. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2000; 25:199-200.
33. Mercie P, Viallard JF, Thiebaut R, et al. Efavirenz-associated breast hypertrophy in HIV-infection patients. AIDS 2001; 15:126-9.
34. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84:1932-7.
35. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-9.
36. Meininger G, Hadigan C, Rietschel P, Grinspoon S. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 2002; 76:460-5.
37. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-62.
38. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54:254-60.
39. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ 1984; 288:1401-4.
40. Deedwania PC. The deadly quartet revisited. Am J Med 1998; 105:1-3S.
41. Garg A. Lipodystrophies. Am J Med 2000; 108:143-52.
42. Heyligenberg R, Romijn JA, Hommes MJ, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Non-insulin-mediated glucose uptake in human immunodeficiency virus-infected men. Clin Sci 1993; 84:209-16.
43. Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40:651-6.
44. Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Basal fuel homoeostasis in symptomatic human immunodeficiency virus infection. Clin Sci 1991; 80:359-65.
45. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77:956-62.
46. Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991; 3:143-58.
47. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
48. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-52.
49. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76:1423-7.
50. Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992; 339:453-6.
51. Lister RK, Youle M, Nair DR, Winder AF, Rustin MH. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet 1999; 353:1678.
52. Behrens G, Schmidt HH, Stoll M, Schmidt RE. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet 1999;354:76.
53. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. Aids 2001; 15:F11-8.
54. Noor M, Seneviratne T, Aweeka F, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized placebo-controlled study. AIDS 2002 16:F1-8.
55. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251-4.
56. Hruz PW, Mueckler MM. Structural analysis of the GLUT1 facilitative glucose transporter. Mol Membr Biol 2001; 18:183-93.
57. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14:51-7.
58. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15:2407-14.
59. Despres JP, Prud'homme D, Pouliot MC, Tremblay A, Bouchard C. Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men. Am J Clin Nutr 1991; 54:471-7.
60. Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr 1999; 69:381-7.
61. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-97.